Crestor Atherosclerosis Indication Adds Point Of Difference, Brand Leader Says
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca will build atherosclerosis benefit of Crestor into “messaging” of the statin to physicians, Commercial Brand Leader Nanfra says in an interview with “The Pink Sheet” DAILY.
You may also be interested in...
Clinical And Economic Implications Of Crestor JUPITER Study Headline ACC Meeting
Planet-struck American College of Cardiology kicks off its annual scientific session with a focus on the impact of AstraZeneca’s high-profile rosuvastatin study for medical practice and for the economics of cardiac health care.
Clinical And Economic Implications Of Crestor JUPITER Study Headline ACC Meeting
Planet-struck American College of Cardiology kicks off its annual scientific session with a focus on the impact of AstraZeneca’s high-profile rosuvastatin study for medical practice and for the economics of cardiac health care.
AstraZeneca’s GALAXY Studies And Plans For Crestor’s Ongoing Development
Company executives discuss on-going efforts to differentiate Crestor in the increasingly crowded cholesterol-lowering market.